Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6233788 | 0.95 | FLT3 (0.53) | MAPK14PTK2MAPK13CYP2D6CYP2C9 | |
| SCHEMBL6080298 | 0.94 | MAPK14 (0.56) | MAPK14PTK2MAPK13CYP2D6CYP2C9 | |
| SCHEMBL6079909 | 0.94 | MAPK14 (0.56) | MAPK14PTK2MAPK13CYP2D6CYP2C9 | |
| SCHEMBL6079684 | 0.94 | MAPK13 (0.60) | MAPK14PTK2MAPK13MAPK12MAPK11 | |
| SCHEMBL6079363 | 0.92 | MAPK14 (0.49) | MAPK14PTK2MAPK13CYP2D6CYP2C9 | |
| SCHEMBL6078855 | 0.88 | BRAF (0.54) | MAPK14PTK2MAPK13MAPK12MAPK11 | |
| SCHEMBL6079432 | 0.87 | PTK2 (0.42) | MAPK14PTK2MAPK13CYP2D6CYP2C9 | |
| SCHEMBL6080266 | 0.85 | MAPK14 (0.43) | MAPK14PTK2MAPK13MAPK12MAPK11 | |
| SCHEMBL6079268 | 0.83 | KCNJ6 (0.52) | BRAF | |
| SCHEMBL6079364 | 0.83 | MAPK14 (0.43) | MAPK14PTK2MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | MAPK14 20/4885PTK2 889/4885MAPK13 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.